Alopecia areata: review of epidemiology, pathophysiology, current treatments and nanoparticulate delivery system

被引:2
作者
Singh, Robel [1 ]
Soni, Pawan [2 ]
Kumar, Davinder [1 ]
Aggarwal, Navidha [3 ]
Chopra, Hitesh [4 ]
Kumar, Virender [1 ]
机构
[1] Univ Hlth Sci Rohtak, Coll Pharm, PGIMS, Pt BD Sharma, Rohtak 124001, India
[2] Govt India, Minist Hlth & Family Welf, Indian Pharmacopoeia Commiss, Ghaziabad, India
[3] Maharishi Markandeshwar Deemed Univ, MM Coll Pharm, Mullana 133207, Ambala, India
[4] Saveetha Inst Med & Tech Sci, Saveetha Sch Engn, Dept Biosci, Chennai 602105, Tamil Nadu, India
关键词
alopecia areata; auto-immune disorder; clobetasol propionate; exuberate; Injectable modalities; nanoparticulate drug delivery; nonscarring; systemic illness; CLOBETASOL PROPIONATE 0.05-PERCENT; TOPICAL MINOXIDIL; LIPID NANOPARTICLES; DRUG-DELIVERY; HAIR FOLLICLE; DERMAL DELIVERY; DOUBLE-BLIND; THERAPY; PREVALENCE; EFFICACY;
D O I
10.4155/tde-2023-0071
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Alopecia areata (AA) is a kind of alopecia that affects hair follicles and nails. It typically comes with round patches and is a type of nonscarring hair loss. Various therapies are accessible for the management and treatment of AA, including topical, systemic and injectable modalities. It is a very complex type of autoimmune disease and is identified as round patches of hair loss and may occur at any age. This review paper highlights the epidemiology, clinical features, pathogenesis and new treatment options for AA, with a specific emphasis on nanoparticulate drug-delivery systems. By exploring these innovative treatment approaches, researchers aim to enhance the effectiveness and targeted delivery of therapeutic agents, ultimately improving outcomes for individuals living with AA.
引用
收藏
页码:193 / 210
页数:18
相关论文
共 101 条
[81]   Profile of alopecia areata in northern India [J].
Sharma, VK ;
Dawn, G ;
Kumar, B .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 1996, 35 (01) :22-27
[82]   Transdermal delivery of mixnoxidil with block copolymer nanoparticles [J].
Shim, J ;
Kang, HS ;
Park, WS ;
Han, SH ;
Kim, J ;
Chang, IS .
JOURNAL OF CONTROLLED RELEASE, 2004, 97 (03) :477-484
[83]   A Tutorial for Developing a Topical Cream Formulation Based on the Quality by Design Approach [J].
Simoes, Ana ;
Veiga, Francisco ;
Vitorino, Carla ;
Figueiras, Ana .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 107 (10) :2653-2662
[84]  
Singh Gurcharan, 2010, Int J Trichology, V2, P36, DOI 10.4103/0974-7753.66911
[85]   Minoxidil and its use in hair disorders: a review [J].
Suchonwanit, Poonkiat ;
Thammarucha, Sasima ;
Leerunyakul, Kanchana .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 :2777-2786
[86]  
Surber KS., 2006, NANOSCI NANOTECHNOL, DOI [10.1002/9783527692057.ch16, DOI 10.1002/9783527692057.CH16]
[87]  
Thappa D M, 2001, Indian J Dermatol Venereol Leprol, V67, P188
[88]  
Thomas Emy Abi, 2008, Indian J Dermatol, V53, P70, DOI 10.4103/0019-5154.41650
[89]   Penetration profile of microspheres in follicular targeting of terminal hair follicles [J].
Toll, R ;
Jacobi, U ;
Richter, H ;
Lademann, J ;
Schaefer, H ;
Blume-Peytavi, U .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 123 (01) :168-176
[90]   Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis [J].
Tosti, A ;
Piraccini, BM ;
Pazzaglia, M ;
Vincenzi, C .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (01) :96-98